Last reviewed · How we verify
Induction Cycles A1-A3
Induction Cycles A1-A3 is a treatment regimen for patients undergoing hematopoietic stem cell transplantation.
Induction Cycles A1-A3 is a treatment regimen for patients undergoing hematopoietic stem cell transplantation. Used for Hematopoietic stem cell transplantation.
At a glance
| Generic name | Induction Cycles A1-A3 |
|---|---|
| Sponsor | Nationwide Children's Hospital |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This regimen involves a series of chemotherapy cycles to prepare the patient for transplantation, with the goal of inducing a state of remission or reducing the risk of complications during the transplant process.
Approved indications
- Hematopoietic stem cell transplantation
Common side effects
- Nausea
- Vomiting
- Fatigue
- Hair loss
- Infection
Key clinical trials
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML (PHASE1)
- A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies (PHASE1)
- A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers. (PHASE1)
- Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma (PHASE3)
- A Study of Danavorexton in Anesthetized Adults (PHASE1)
- A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). (PHASE1)
- A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) (PHASE1)
- A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Induction Cycles A1-A3 CI brief — competitive landscape report
- Induction Cycles A1-A3 updates RSS · CI watch RSS
- Nationwide Children's Hospital portfolio CI